Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a proof-of-concept study of OBE022 plus atosiban in pregnant women at risk of spontaneous preterm birth
MOH_2018-05-07_002368Phase 2Not yet recruiting
- Sponsor
- ObsEva SA
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Preterm labor (PTL) comparing OBE022 oral + atosiban infusion with Placebo oral + atosiban infusion (2 arms). Primary endpoints: Efficacy, Safety and 1 more. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
ebopiprant
03
Conditions
Preterm labor (PTL)
Beyond the preview
Go deeper on MOH_2018-05-07_002368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-07_002368.